FDA-approved drug shows promise as alcoholism treatment

Jan 12, 2011

(PhysOrg.com) -- A medication commonly prescribed as a muscle relaxant shows promise as a potential treatment for alcoholism, based on a study in rats by researchers at the Ernest Gallo Clinic and Research Center and the University of California, San Francisco.

Chlorzoxazone, an FDA-approved drug, significantly decreased in a of heavy drinking, said lead author Woody Hopf, PhD, an associate investigator at Gallo and an assistant adjunct professor of neurology at UCSF.

The study appeared online in (Jan. 3, 2011).

Hopf and his colleagues found that, among rats that have been trained to drink large amounts of alcohol, chlorzoxazone activates the SK-type potassium channel in neurons, which makes the neurons less excitable. The drug’s action takes place in the nucleus accumbens, a brain region that in both rodents and humans is part of the reward system that affects craving for alcohol and other addictive substances.

The ability of chlorzoxazone to reduce neuronal excitability is “important,” Hopf explained, “because the more excitable neurons in the nucleus accumbens are, the more they respond to the stimulation provided by alcohol, which in turn drives alcohol-seeking behavior.”

Applying the results of his previous research to the current study, Hopf found that rats that habitually drink heavily have fewer SK channels in their than rats without an alcohol habit. In the current study, Hopf demonstrated that when the rats’ remaining SK channels were activated, “the excitability of the nucleus accumbens was turned down, and this, in turn, suppressed alcohol drinking in heavy-drinking rats.”

Hopf sees chlorzoxazone as a possible alcohol-abuse medication among patients for whom currently available drugs do not work, or among patients who do not take the drugs because of adverse or unpleasant side effects. In particular, “this might work for an alcoholic who is in abstinence, and who is doing OK, but who during a critical or stressful period is in danger of going back to drinking,” said Hopf. “Chlorzoxazone might be exactly the kind of drug to take the edge off that craving, without side effects.”

Hopf said that the next logical step in his research is a clinical trial, “which could begin immediately,” since chlorzoxazone is already approved as a medication. He says the trial could be conducted by the Gallo Center, “since we have an in-house clinical trials group with tremendous expertise.”

Co-authors of the study are Jeffrey A. Simms, BS, Shao-Ju Chang, BA, Taban Seif, PhD, and Selena E. Bartlett, PhD, of the Gallo Center, and senior author Antonello Bonci, MD, an adjunct professor of neurology at the Gallo Center and UCSF and Scientific Director of the Intramural Research Program at the National Institute on Drug Abuse.

The study was supported by funds from the National Institute on Abuse and Alcoholism, the State of California, and the U.S. Department of Defense.

Explore further: Researchers tackle 'virtually ignored' psychological study of spite

More information: Biological Psychiatry:
“Chlorzoxazone, an SK-Type Potassium Channel Activator Used in Humans, Reduces Excessive Alcohol Intake in Rats”
www.biologicalpsychiatryjournal.com/article/S0006-3223%2810%2901172-8/abstract

Provided by University of California, San Francisco

3 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Excessive drinking and relapse rapidly cut in new approach

Jun 09, 2008

Boosting the level of a specific brain protein quickly cut excessive drinking of alcohol in a new animal study, and also prevented relapse -- the common tendency found in sober alcoholics to easily return to heavy drinking ...

Drug decreases alcohol cravings

Nov 02, 2010

Rapamycin, an FDA-approved drug prescribed to prevent the rejection of transplanted organs, has been shown for the first time to decrease excessive alcohol consumption, binge drinking, and alcohol-seeking behavior in rodents. ...

Biochemical pathway may link addiction, compulsive eating

Sep 01, 2010

Ezlopitant, a compound known to suppress craving for alcohol in humans, was shown to decrease consumption of sweetened water by rodents in a study by researchers at the Ernest Gallo Clinic and Research Center, which is affiliated ...

New study reveals brain cell mechanism of alcohol dependence

May 28, 2008

A study released today reveals a cellular mechanism involved in alcohol dependence. The study, in the May 28 issue of The Journal of Neuroscience, shows that gabapentin, a drug used to treat chronic pain and epilepsy, reduce ...

Recommended for you

Offenders turn to mental health services 

4 hours ago

Adult criminal offenders in Western Australian are eight times more likely than non-offenders to use community-based mental health services in the year before their first sentence, a UWA study has found.

Deliberation is staunchest ally of selfishness

5 hours ago

(Medical Xpress)—Over the last two years, Yale psychologist David Rand and colleagues have investigated what makes people willing to help each other. Their latest research shows that while initial reactions ...

User comments : 0

More news stories

Cyber buddy is better than 'no buddy'

A Michigan State University researcher is looking to give exercise enthusiasts the extra nudge they need during a workout, and her latest research shows that a cyber buddy can help.